Lung Cancer Clinical Trial

Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways

Summary

The purpose of this study is to demonstrate that combined stereotactic body radiotherapy and radiofrequency ablation is safe for patients with lung tumors near central airways.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed primary lung cancer, lung metastasis from another primary, or recurrent tumors in the setting of prior RFA or cryotherapy
Tumors < 2 cm from trachea or zone of proximal bronchial tree (central tumors)
Each tumor < 5 cm in size prior to treatment
Medically inoperable patients as determined at the multidisciplinary thoracic tumor board, or medically operable patients who refuse surgery

Criterion for medical inoperability include:

Overall clinical assessment at the UCLA thoracic tumor board
Reduced Pulmonary Function (FEV1, DLCO, etc) based on one major or two minor criterion as described below:

Modified ACOSOG Criteria for medical inoperability:

Major Criteria: FEV1% < 50% or < 1L and DLCO < 50%
Minor Criteria: Age > 75, FEV1 51-60% predicted, or FEV1 1-1.2L, DLCO 51%-60% predicted, pulmonary hypertension, poor left ventricular function (EF < 40% or less), resting or exercise arterial pO2 < 55 mmHg, and pCO2 > 45 mmHg
Age > 18 years old
KPS > 70
If a woman is of childbearing potential, a negative urine or serum pregnancy test must be documented.
Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

Prior thoracic radiation near the targets of interest
More than 2 central tumor targets per patient
Active infections requiring systemic antibiotics

Study is for people with:

Lung Cancer

Estimated Enrollment:

17

Study ID:

NCT01051037

Recruitment Status:

Completed

Sponsor:

Jonsson Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

UCLA Jonsson Comprehensive Cancer Center
Los Angeles California, 90095, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

17

Study ID:

NCT01051037

Recruitment Status:

Completed

Sponsor:


Jonsson Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider